Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Return vs. Strategy

This article was originally published in Start Up

Executive Summary

Corporate venture funds walk a fine line between investing to access cutting edge technology and investing for return. But now SR One, SmithKline Beecham's in-house venture fund, can have it both ways. With venture firm Euclid Partners, SR One has formed a new $200 million fund, EuclidSR Partners, with SmithKline Beecham contributing a significant amount of money as a limited partner.

You may also be interested in...



Corporate Venture Capital's Complex Agenda

Several forces--rapid technological obsolescence, the impact of information technology on health care, merger integrations, and the need for double digit revenue growth--have caused increasing numbers of large pharmaceutical and medical device companies to create new corporate venture capital groups. But compared to traditional VC firms, whose only goal is to make money for limited partners, corporate VCs have a heavy agenda. They must choose portfolio companies while balancing often-competing goals of strategic benefit and financial return.

SR One

SR One is a rare example of a corporate venture capital fund, with this one the product of SmithKline Beecham.

Corporate Venturing

Advice of Counsel addresses whether pharamaceutical and device companies are good sources of venture capital for early-stage companies.

Topics

Related Companies

UsernamePublicRestriction

Register

SC090208

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel